0001179110-21-008140.txt : 20210812 0001179110-21-008140.hdr.sgml : 20210812 20210812100022 ACCESSION NUMBER: 0001179110-21-008140 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210810 FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martin Samuel Bates CENTRAL INDEX KEY: 0001709024 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 211165768 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 edgar.xml FORM 4 - X0306 4 2021-08-10 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001709024 Martin Samuel Bates C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD HAMPTON NJ 08827 0 1 0 0 SVP and CFO Common Stock 2021-08-10 4 M 0 10302 9.0165 A 21037 D Common Stock 2021-08-10 4 S 0 2056 45.25 D 18981 D Common Stock 2021-08-10 4 M 0 11079 2.78 A 30060 D Common Stock 2021-08-10 4 S 0 682 45.25 D 29378 D Incentive Stock Option 9.0165 2021-08-10 4 M 0 10302 0.00 D 2028-06-13 Common Stock 10302 16030 D Incentive Stock Option 2.78 2021-08-10 4 M 0 11079 0.00 D 2029-06-19 Common Stock 11079 31921 D On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction. 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin 2021-08-12